Funds managed by S&C client Oaktree Capital Management provided a $225 million senior secured term loan to Athenex Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel cancer treatments. In addition, Oaktree received warrants to purchase Athenex’s common stock. Athenex will use the funds to refinance its debt and fund the launch of new therapies.
The S&C team was led by Ari Blaut
, co-head of the Firm’s U.S. Credit & Leveraged Finance
practice. Mehdi Ansari
advised on intellectual property
matters and Ron Creamer advised on tax matters.